ACR Convergence 2025| Video: Rheuminations on Milestones & Ageism

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: cancer

In Memoriam … J. Timothy Harrington, MD, MACR: July 6, 1940–June 23, 2020

William Arnold, MD; Tim Bartholow, MD; Drew Johnson, MS, MBA; Joel Kremer, MD; Daniel Malone, MD; Eric D. Newman, MD; Kenneth Saag, MD; & Douglas White, MD  |  June 30, 2020

June saw the passing of a beloved colleague, mentor and friend to many in the rheumatology community when J. Timothy Harrington, MD, died of pancreatic cancer in his hometown of Madison, Wis. Dr. Harrington trained at Massachusetts General Hospital, the National Institutes of Health National Cancer Institute and UT Southwestern Medical Center, and served on…

Filed under:Professional TopicsProfiles Tagged with:Dr. J. Timothy HarringtonHarrington

Spring 2020’s Awards, Appointments & Announcements in Rheumatology

Gretchen Henkel  |  June 15, 2020

Keith Sullivan, MD, Receives Lifetime Achievement Award Mentorship, collaboration and a quest for cure shine through as major themes in the distinguished career of Keith M. Sullivan, MD, the James B. Wyngaarden Professor of Medicine, Duke University Medical Center, Durham, N.C. On Friday, Feb. 21, those themes dominated his acceptance speech when he received a…

Filed under:AwardsProfiles Tagged with:Dr. Daniel AletahaDr. Keith M. SullivanDr. Michael S. PutmanMovers & Shakers

A Peaceful Medical Mission in Guatemala, Days before COVID-19

Daniel F. Battafarano, DO, MACP, FACR  |  June 15, 2020

My first-ever medical mission trip, after 37 years of medical practice, was to Teleman, Alta Verapaz, Guatemala. Prior to the trip, my excitement as an adult-trained rheumatologist was balanced against my apprehension about witnessing new diseases, caring for children and practicing in an austere environment with limited medical resources. As directed by the travel clinic,…

Filed under:Career Development Tagged with:medical missionsVolunteering

nukeaf / shutterstock.com

The History of Treating Lupus with Hydroxychloroquine

Ruth Jessen Hickman, MD  |  June 15, 2020

Given how unexpectedly front and center hydroxychloroquine has been in discussions about the treatment of COVID-19 this year, it makes sense to look at how it became so central to the treatment of a rheumatologic condition. In 1991, an article appeared in The New England Journal of Medicine that would alter the way rheumatologists approached…

Filed under:ConditionsSystemic Lupus Erythematosus Tagged with:Lost & Foundretinopathy

Diagnosing & Treating Hemophagocytic Lymphohistiocytosis in Adults

Srujana Pachigolla, MD, & Adegbenga Bankole, MD  |  June 15, 2020

Primary hemophagocytic lymphohistiocytosis (HLH) is caused by genetic mutations and inherited syndromes; it therefore occurs in the pediatric age group. Secondary HLH, however, is more common in adults and is often triggered by other disease states, such as malignancies, chronic immuno­suppression, infections and autoimmune disease.1,2 Macrophage activation syndrome (MAS) is a subset of secondary HLH…

Filed under:ConditionsVasculitis Tagged with:case reporthemophagocytic lymphohistiocytosishemophagocytic lymphohistiocytosis (HLH)HLHmacrophage activation syndrome

We Make a Difference

Philip Seo, MD, MHS  |  June 15, 2020

“No!” she screamed. My niece just finished her first semester as a freshman at the University of St. Andrews in Scotland. If the institution sounds familiar to you, it may be because you remember a particularly famous graduate—William Windsor, who sometimes goes by his formal titles: Duke of Cambridge and heir to the British throne….

Filed under:ConditionsOpinionRheuminationsSpeak Out Rheum Tagged with:COVID-19

Serological Antibody Tests in COVID-19: Test Reliability and Utility

Ruth Jessen Hickman, MD  |  June 10, 2020

Serological testing for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies may play a critical role in the management of the worldwide health crisis. Such testing may reveal key information for epidemiology, convalescent plasma therapies and vaccine development. However, the situation is complex, and much is unknown. Although such testing may ultimately be used to…

Filed under:Conditions Tagged with:COVID-19Testing

U.S. Insurers Often Limit Biosimilar Coverage

Lisa Rapaport  |  May 29, 2020

(Reuters Health)—U.S. commercial health plans only covered biosimilar treatments as preferred products in 14% of coverage decisions last year, according to an analysis of publicly available data on coverage decisions.1 Researchers examined records from the Tufts Medical Center Specialty Drug Evidence and Coverage (SPEC) database, which has information on coverage decisions made by 17 of…

Filed under:Biologics/DMARDsDrug Updates Tagged with:BiosimilarsHealth Insuranceinfliximab-abdainfliximab-dyybpharmacy benefit managers (PBMs)

Long-Term Biologic Use May Not Raise Melanoma Risk

Marilynn Larkin  |  May 29, 2020

NEW YORK (Reuters Health)—Patients treated with biologic therapy for rheumatoid arthritis, inflammatory bowel disease and psoriasis don’t appear to be at increased risk of melanoma, according to the results of a systematic review and meta-analysis. However, because the study found trends toward increased melanoma rates with long-term therapy, “a clinically meaningful increase in risk cannot…

Filed under:Drug Updates Tagged with:Biologicsmelanomaskinskin cancer

The initial physical examination was significant for a nonblanching, papular rash along the palmar aspects of the hands and digits, periungual erythema, and edema and tenderness of the proximal and distal interphalangeal joints of the hands.

Case Report: A Patient with Clinically Amyotrophic Dermatomyositis & Associated ILD & RA Overlap

Vania Lin, MD, MPH, & Leah Krull, MD  |  May 15, 2020

Clinically amyotrophic dermatomyositis (CADM), a subset of dermatomyositis (DM), is a rare autoimmune disease characterized by typical DM cutaneous findings (e.g., heliotrope rash, Gottron papules, Gottron sign) without evidence of myositis.1 The incidence of DM and CADM is approximately 9.63 per 1 million people and 2.08 per 1 million people, respectively.2 The association with development…

Filed under:ConditionsRheumatoid Arthritis Tagged with:Clinically Amyotrophic Dermatomyositis (CADM)combination therapyinterstitial lung disease (ILD)

  • « Previous Page
  • 1
  • …
  • 23
  • 24
  • 25
  • 26
  • 27
  • …
  • 85
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences